Picture of RxSight logo

RXST — RxSight News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Rxsight Inc expected to post a loss of 36 cents a share - Earnings Preview

* Rxsight Inc  RXST.OQ   RXST.O  is expected to show a rise
in
quarterly revenue when it reports  results on February 28 for
the period ending December 31 2023
    * The Aliso Viejo California-based  company is expected to
report
a 70.5% increase in revenue to $27.427 million from $16.09
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Rxsight Inc is for a
loss
of 36 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Rxsight Inc
is
$53.00​, below​ its last closing price of $56.41. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.43       -0.43      -0.31     Beat    28.5
 Jun. 30 2023  -0.47       -0.47      -0.39     Beat    17
 Mar. 31 2023  -0.53       -0.53      -0.42     Beat    20.8​
 Dec. 31 2022  -0.77       -0.75      -0.56     Beat    25.1
 ​​Sep.        -0.71       -0.71      -0.61     Beat    14.5
 30 2022                                                
 Jun. 30 2022  -0.69       -0.69      -0.61     Beat    12.2​
 Mar. 31 2022  -0.65       -0.65      -0.64     Beat    1
 Dec. 31 2021  -0.73       -0.68      -0.58     Beat    15
 This summary was machine generated February 27 at 02:06 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on RxSight

See all news